December 9, 2022

Global IV Paracetamol Industry Expected to Reach $1.2 Billion by 2027: Increased Use of Acetaminophen to Reduce Dependence on Opioids for Pain Management Drives Growth –

DUBLIN–(BUSINESS WIRE)–The report “Paracetamol IV Market Research Report by Indication, Application, End-use, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” has been added to from offer.

The global Paracetamol IV market size was estimated at USD 821.23 million in 2021, USD 878.46 million in 2022, and is projected to grow at a CAGR of 7.22% to reach USD 1,248.07 million by 2027.

Competitive Strategy Window:

The strategic competitive window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or match between its capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for vendors to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to execute further business expansion and growth. during a forecast period.

FPNV positioning matrix:

The FPNV Positioning Matrix evaluates and ranks vendors in the Paracetamol IV Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (value for money, ease of use, product features, and customer support) that helps businesses make better decisions and better understand the competitive landscape.

Market share analysis:

The market share analysis offers the analysis of the vendors considering their contribution to the overall market. It gives the idea of ​​its revenue generation in the overall market compared to other providers in the space. It provides information on the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of suppliers for the reference year. It reveals the characteristics of the market in terms of accumulation, fragmentation, dominance and merger.

The report provides information about the following pointers:

1. Market Penetration: Provides comprehensive information about the market offered by major players

2. Market Development: Provides detailed information on lucrative emerging markets and analyzes penetration in mature market segments

3. Market Diversification: Provides detailed information on new product launches, untapped geographies, recent developments and investments

4. Competitive Assessment and Intelligence: Provides a comprehensive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of key players

5. Product Development and Innovation: Provides smart insights into future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the global Paracetamol IV market?

2. What are the inhibiting factors and impact of COVID-19 on the Global IV Paracetamol Market during the forecast period?

3. What are the products/segments/applications/areas to invest in during the forecast period in the Global Paracetamol IV Market?

4. What is the competitive strategic window for opportunities in the Global Paracetamol IV Market?

5. What are the technological trends and regulatory frameworks in the global paracetamol IV market?

6. What is the market share of the major vendors in the global IV paracetamol market?

7. What modes and strategic moves are considered suitable for entering the global paracetamol IV market?

Market dynamics


  • Growing prevalence and burden of indicative diseases and conditions

  • Increased use of IV paracetamol for fever relief in post-surgical procedures

  • Increased use of acetaminophen to reduce reliance on opioids for pain management


  • Availability of several generic products


  • Government initiatives and increasing research and development activities

  • Use of IV paracetamol in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) and narcotics


  • Lack of experienced healthcare professionals

Companies cited

  • Aurobindo Pharma Ltd.

  • Organic E. Limited

  • Bristol-Myers Squibb Company

  • Cfl Pharmaceuticals Limited

  • Changshu Huagang Pharmaceuticals Co., Ltd.

  • Cipla inc.

  • Dr. Reddy’s Laboratories Ltd.

  • Genesis Biotec Inc.

  • Geno Pharmaceuticals Private Limited

  • GlaxoSmithKline plc.

  • Hebei Jiheng Pharmaceutical Co., Ltd.

  • Huzhou Konch Pharmaceutical Co., Ltd.

  • Lupine Limited

  • Mallinckrodt plc

  • Novartis AG

  • Pfizer Inc.

  • Sanofi-Aventis Deutschland GmbH

  • Sun Pharmaceutical Industries Limited

  • Teva Pharmaceutical Industries Ltd.

  • Zhejiang Kangle Pharmaceutical Co., Ltd.

For more information on this report visit